Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14630 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2024. Written by Olga N Zhukovskaya and 10 co-authors. Institution: Institute of Physical and Organic Chemistry, Southern Federal University, Russian Federation, Rostov-on-Don, Russia. Major MEDLINE topics: Thiazoles. 29 references. Funded by: Centenarian League LLC.
Abstract (original language)
Preliminary ab initio calculations led to the synthesis of novel substituted thiazolium salts, analogs of Alagebrium, which were further explored in vitro for their potential as inhibitors of the glycation reaction utilizing three distinct assays: inhibition of fluorescent AGEs formation, anticrosslinking, and deglycation. Despite the unidirectionality of the assays, distinct differences were observed in the mechanisms of interference and activity manifestation by the compounds. The gathered data permitted the formation of hypotheses about the molecular fragments of the studied antiglycators that are of utmost significance in each assay, thereby guiding future design endeavors. Potential mechanisms of actions are discussed therein. The compound 4‐meth‐yl‐3‐[2‐(4‐methylbiphenyl‐4‐yl)‐2‐oxoethyl] thiazolium bromide displayed high activity across all three assays, establishing it as a lead compound. The cytotoxicological properties of the compounds were evaluated using LDH and MTT assays. However, the lead compound exhibited cytotoxicity, indicating the need for additional investigations aimed at decreasing toxicity while maintaining activity. The targeted thiazolium salts were synthesized through an N ‐alkylation reaction between the corresponding thiazoles and phenacyl bromides.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Physical and Organic Chemistry, Southern Federal University, Russian Federation, Rostov-on-Don, Russia.
- Volgograd State Medical University, Scientific Center for Innovative Drugs, Volgograd, Russia.
- Department of Organic Chemistry, North Caucasus Federal University, Stavropol, Russia.
ORCID profiles: Olga N Zhukovskaya, Alexandra A Kolodina, Roman Litvinov, Umida Ibragimova, Nikita Valuisky, Svetlana Sorokina, Xenia Zhukova, Diana Yu Pobedinskaya, Alexander Borisov, Denis A Babkov, Alexander A Spasov
Funding
- Centenarian League LLC
Cite
APA
Zhukovskaya, O. N., Kolodina, A. A., Litvinov, R., Ibragimova, U., Valuisky, N., Sorokina, S., Zhukova, X., Pobedinskaya, D. Y., Borisov, A., Babkov, D. A., & Spasov, A. A. (2024). Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14630
Vancouver
Zhukovskaya ON, Kolodina AA, Litvinov R, Ibragimova U, Valuisky N, Sorokina S, et al. Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14630
BibTeX
@article{Zhukovskaya2024,
author = {Zhukovskaya, Olga N and Kolodina, Alexandra A and Litvinov, Roman and Ibragimova, Umida and Valuisky, Nikita and Sorokina, Svetlana and Zhukova, Xenia and Pobedinskaya, Diana Yu and Borisov, Alexander and Babkov, Denis A and Spasov, Alexander A},
title = {Directed Design, Screening and Antiglycation Activity for 3‐Substituted Thiazolium Derivatives, New Analogs of Alagebrium},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14630}
}
EUVIMED